[
  {
    "ts": "2025-12-12T11:47:00+00:00",
    "headline": "Arcus cancels work on Gilead-partnered cancer combo after trial setback",
    "summary": "A study using TIGIT and PD-1 drugs for gastrointestinal disease was canceled for “futility” at an early checkpoint, another blow to research on a once-promising target.",
    "url": "https://www.biopharmadive.com/news/arcus-gilead-domvanalimab-trial-terminate/807761/",
    "source": "BioPharma Dive",
    "provider": "yfinance",
    "raw": {
      "id": "a0362a0a-cdf9-3dbb-8e7e-b3e29d424eaa",
      "content": {
        "id": "a0362a0a-cdf9-3dbb-8e7e-b3e29d424eaa",
        "contentType": "STORY",
        "title": "Arcus cancels work on Gilead-partnered cancer combo after trial setback",
        "description": "",
        "summary": "A study using TIGIT and PD-1 drugs for gastrointestinal disease was canceled for “futility” at an early checkpoint, another blow to research on a once-promising target.",
        "pubDate": "2025-12-12T11:47:00Z",
        "displayTime": "2025-12-12T11:47:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/biopharma_dive_768/109565b4f0080973d0a1aa2d231b9288",
          "originalWidth": 1600,
          "originalHeight": 900,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/8I7YEXLOCmt6YjWoFjq7JQ--~B/aD05MDA7dz0xNjAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/biopharma_dive_768/109565b4f0080973d0a1aa2d231b9288.cf.webp",
              "width": 1600,
              "height": 900,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/ir5McscZAlqHee.HcRcyig--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/biopharma_dive_768/109565b4f0080973d0a1aa2d231b9288.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "BioPharma Dive",
          "url": "https://biopharmadive.com/"
        },
        "canonicalUrl": {
          "url": "https://www.biopharmadive.com/news/arcus-gilead-domvanalimab-trial-terminate/807761/",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/arcus-cancels-gilead-partnered-cancer-114700611.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "RCUS"
            },
            {
              "symbol": "GILD"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-12-12T17:35:49+00:00",
    "headline": "Why Arcus Biosciences Just Reversed Its 287% Eight-Month Winning Streak",
    "summary": "Arcus Biosciences stock plunged Friday, reversing a nearly 300% gain, after its Gilead Sciences-partnered cancer regimen failed.",
    "url": "https://www.investors.com/news/technology/arcus-biosciences-gilead-sciences-anti-tigit-failure/?src=A00220&yptr=yahoo",
    "source": "Investor's Business Daily",
    "provider": "yfinance",
    "raw": {
      "id": "f48bab5e-e66c-3b01-82ca-f0a954928223",
      "content": {
        "id": "f48bab5e-e66c-3b01-82ca-f0a954928223",
        "contentType": "STORY",
        "title": "Why Arcus Biosciences Just Reversed Its 287% Eight-Month Winning Streak",
        "description": "",
        "summary": "Arcus Biosciences stock plunged Friday, reversing a nearly 300% gain, after its Gilead Sciences-partnered cancer regimen failed.",
        "pubDate": "2025-12-12T17:35:49Z",
        "displayTime": "2025-12-12T17:35:49Z",
        "isHosted": false,
        "bypassModal": false,
        "previewUrl": "https://finance.yahoo.com/m/f48bab5e-e66c-3b01-82ca-f0a954928223/why-arcus-biosciences-just.html",
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/ibd.com/c41f2b75ef43110c88cfcb472262eb79",
          "originalWidth": 945,
          "originalHeight": 533,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/shVGxj7bu_u.CpYzNTXRdw--~B/aD01MzM7dz05NDU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/ibd.com/c41f2b75ef43110c88cfcb472262eb79.cf.webp",
              "width": 945,
              "height": 533,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/WU5OlgKO09tNMial_TfFPA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/ibd.com/c41f2b75ef43110c88cfcb472262eb79.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Investor's Business Daily",
          "url": "http://www.investors.com/"
        },
        "canonicalUrl": {
          "url": "https://www.investors.com/news/technology/arcus-biosciences-gilead-sciences-anti-tigit-failure/?src=A00220&yptr=yahoo",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": null,
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "RCUS"
            },
            {
              "symbol": "BMY"
            },
            {
              "symbol": "GILD"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-12-12T15:30:00+00:00",
    "headline": "Kymera's Eczema Drug Gets Fast Track Designation in the United States",
    "summary": "KYMR gains momentum as the FDA grants Fast Track to KT-621 for moderate to severe atopic dermatitis, boosting the stock and advancing its Type 2 pipeline.",
    "url": "https://finance.yahoo.com/news/kymeras-eczema-drug-gets-fast-153000798.html",
    "source": "Zacks",
    "provider": "yfinance",
    "raw": {
      "id": "fe5eb1f0-ed16-326b-9c5e-68eaad7f6e10",
      "content": {
        "id": "fe5eb1f0-ed16-326b-9c5e-68eaad7f6e10",
        "contentType": "STORY",
        "title": "Kymera's Eczema Drug Gets Fast Track Designation in the United States",
        "description": "",
        "summary": "KYMR gains momentum as the FDA grants Fast Track to KT-621 for moderate to severe atopic dermatitis, boosting the stock and advancing its Type 2 pipeline.",
        "pubDate": "2025-12-12T15:30:00Z",
        "displayTime": "2025-12-12T15:30:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/zacks.com/1566882a22938942efee3e7508e93e96",
          "originalWidth": 635,
          "originalHeight": 400,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/nURi29Wh6a5rz6SvQvvCDw--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/1566882a22938942efee3e7508e93e96.cf.webp",
              "width": 635,
              "height": 400,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/gUIojpJE4OxxDca8KkXZsA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/1566882a22938942efee3e7508e93e96.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Zacks",
          "url": "http://www.zacks.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/kymeras-eczema-drug-gets-fast-153000798.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/kymeras-eczema-drug-gets-fast-153000798.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "KYMR"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]